VECTURA GROUP (LSE:VEC)

 

VECTURA GROUP (VEC.L, LSE, LSE:VEC)

VEC Share PerformanceMore

52 week high171.50 19/02/14
52 week low113.25 16/10/14
52 week change -11.00 (-7.91%)
4 week volume7,424,622 26/11/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Declaration

RNS Number: 2384A Vectura Group plc 19 December 2014 Vectura Group plc Director declaration Chippenham, UK - 19 December 2014: In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE:VEC) announces that Dr. Susan Foden, Non-Executive Director of Vectura, has been appointed as a Non-Executive Director of BTG plc (LSE: BTG) with effect from...

Holding(s) in Company

RNS Number: 6816Z Vectura Group plc 12 December 2014 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group Plc 2 Reason for the notification (please tic...

Vectura says positive study results for VR475 in asthma

Vectura Group has published the results of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS...

Positive Phase IIb/III results for VR475 in asthma

RNS Number: 4476Z Vectura Group plc 11 December 2014 Vectura Group plc Vectura's investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a Phase IIb/III trial in severe asthma patients - Results of the clinical study are published today in the European Respiratory Journal (ERJ) - Significant OCS-sparin...

Total Voting Rights

RNS Number: 3914Y Vectura Group plc 01 December 2014 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 December 2014: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision 6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: ...

Vectura granted approval for inhaler

Vectura Group has confirmed that its partner, Sandoz, has been granted marketing authorisation by the regulatory autho...

Czech and Irish Approval for AirFluSal Forspiro

RNS Number: 4389X Vectura Group plc 19 November 2014 Vectura Group plc Approval in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal Forspiro Regulatory authorities in Ireland and Czech Republic grant marketing authorisation for AirFluSal Forspiro Approval for 50-250 g and 50-500 g dosage forms AirFluSal Forspiro already launche...

Vectura upgraded by Investec

Investec has upgraded its recommendation on respiratory disease treatment specialist Vectura (LON:VEC) to buy from ho...